NATCO shifts Crop Health demerger to mid-2027 amid loss
Key highlights
- NATCO estimates the Crop Health Sciences demerger will complete around mid-Calendar Year 2027.
- Crop Health Sciences reported about Rs 10 lakh of segmental profit in the latest quarter.
- Management expects Crop Health Sciences business growth of around 15%-20% for the year.
- NATCO expects about Rs 20 crore of agrochemical EBITDA loss for the financial year.
powered by IRIS

NATCO Pharma Limited now estimates that its Crop Health Sciences demerger will reach mid-Calendar Year 2027, after a rights issue and recapitalisations required a fresh regulatory filing. The Crop Health Sciences segment made about Rs 10 lakh of profit in the latest quarter, but management expects the agrochemical business to report about Rs 20 crore of EBITDA loss for the financial year.
Know Natco Pharma inside out
Results, valuation, peers and who's buying, in one view.
Why has NATCO delayed the Crop Health Sciences demerger?
NATCO has shifted its estimated Crop Health Sciences demerger timing to mid-Calendar Year 2027 because it must make a fresh filing with the Securities and Exchange Board of India, or SEBI. Vice Chairman and Chief Executive Officer Rajeev Nannapaneni said the rights issue and subsequent recapitalisations led the company to return to SEBI rather than proceed on the end-of-financial-year timing raised by an analyst.
The separation must also go through the National Company Law Tribunal, or NCLT, process after the SEBI filing. Management did not provide a filing date, NCLT hearing date or a specific completion month within mid-2027. The revised timing therefore depends on regulatory and tribunal procedures, rather than only on NATCO's operating plan for the Crop Health Sciences segment.
The rights issue has also changed NATCO's financing position outside the demerger process. Chief Financial Officer Amit Parekh said the company repaid its entire loan after raising funds and had no loans outstanding at the time of the call. That repayment does not set the demerger date, but the capital actions that preceded it were among the reasons management cited for the renewed SEBI filing.
Is NATCO Crop Health Sciences profitable in the latest quarter?
NATCO Crop Health Sciences was marginally profitable in the latest quarter, reporting segmental profit of about Rs 10 lakh. Executive Vice President Crop Health Sciences Rajesh Chebiyam called it “slight marginal profitability” and said it represented a positive quarter compared with Q1. The company did not disclose the Q1 segment profit or loss figure in the call.
The latest-quarter profit contrasts with NATCO's expectation that the agrochemical business will lose about Rs 20 crore at the EBITDA level for the financial year. EBITDA means earnings before interest, tax, depreciation and amortisation. Nannapaneni said this expected loss was already included in the company's profit-after-tax guidance, so the quarterly Rs 10 lakh segmental profit does not indicate a full-year EBITDA profit.
Chebiyam said Crop Health Sciences was also dealing with credit-related provisions, although NATCO did not quantify their amount or identify the customers involved. The provisions matter because management described underlying business growth of about 15%-17% while separately reporting the annual EBITDA-loss expectation. This distinction means reported earnings can differ from the pace of the segment's business activity.
How fast does NATCO expect Crop Health Sciences to grow?
NATCO management expects Crop Health Sciences to grow around 15%-20% for the year, following growth of about 15%-17% from last year to this year. Chebiyam said management remained positive on the year's outcome relative to the prior year, despite saying its original aspirations for the segment had been higher.
Management attributed part of the shortfall against those higher aspirations to El Niño-related effects, which Chebiyam described as severe. The call did not quantify the effect on Crop Health Sciences revenue, crop demand, product volumes or margins. It did establish weather disruption as an operating factor alongside credit provisions in the segment's result.
The 15%-20% figure is management's business-growth expectation, rather than a formal revenue, EBITDA or profit target. It also applies while Crop Health Sciences remains part of NATCO, as Nannapaneni said the demerger will not occur in the current financial year. Consequently, the expected Rs 20 crore agrochemical EBITDA loss remains within NATCO's earnings for that period.
Got a follow-up? Ask IRIS
How does Crop Health Sciences compare with NATCO's other businesses?
NATCO's domestic pharmaceutical base business was about Rs 135 crore a quarter, compared with roughly Rs 100 crore to Rs 110 crore a quarter until last year. Nannapaneni attributed part of the increase to semaglutide sales of Rs 6 crore to Rs 7 crore and to risdiplam. These pharmaceutical products are separate from the Crop Health Sciences portfolio and do not change the segment's Rs 20 crore expected annual EBITDA loss.
Management said the domestic pharmaceutical business had received a roughly 20% bump and internally targeted another 15%-20% compounding next year. That internal target is for the domestic pharmaceutical business, not Crop Health Sciences. The two businesses therefore share similar growth ranges in management commentary but have different products, profitability profiles and demand drivers.
At the consolidated level, NATCO described a recurring quarterly base of about Rs 850 crore to Rs 900 crore, with one-time sales taking the figure to about Rs 1,000 crore. Management said the international generics business included a one-time sale. This makes the Crop Health Sciences result relevant to a broader earnings mix that can also be affected by non-recurring generics transactions.
What could affect NATCO before the Crop Health separation?
NATCO's Crop Health Sciences outcome before mid-2027 will depend on whether it can sustain the expected 15%-20% business growth while addressing credit-related provisions and El Niño-related disruption. The latest-quarter Rs 10 lakh profit marked improvement from Q1, but it sits alongside management's estimate of about Rs 20 crore in annual agrochemical EBITDA loss. Management did not disclose a separate post-demerger financial target for the business.
The timetable will also depend on the new SEBI filing and the subsequent NCLT process. NATCO has disclosed mid-Calendar Year 2027 as its estimate but has not stated whether the refiling changes the separation structure. Until that process is completed, the agrochemical business and its expected EBITDA loss remain reflected in NATCO's reported earnings.
NATCO also expects three pharmaceutical launches in the coming quarters: carfilzomib, trabectedin and olaparib. Nannapaneni said their performance would drive earnings. These launches are outside Crop Health Sciences, but they may affect NATCO's overall earnings profile during the period in which the agrochemical business remains consolidated.
Conclusion
NATCO is pursuing the Crop Health Sciences separation on a longer timetable, with a mid-Calendar Year 2027 estimate replacing the earlier end-of-financial-year expectation discussed on the call. The business has returned to marginal quarterly profitability at about Rs 10 lakh, yet management's expected Rs 20 crore annual EBITDA loss shows that provisions, weather-related disruption and results in other periods remain consequential.
The next disclosed milestones are the renewed SEBI filing and progress through the NCLT process, for which NATCO gave no specific dates beyond mid-2027. Operationally, investors can watch whether Crop Health Sciences delivers management's 15%-20% growth expectation and whether the planned carfilzomib, trabectedin and olaparib launches affect NATCO's wider earnings before the separation.


